July 2, 2018

Open Call for Applicants forinvestigator-Initiated Clinical Research Funds- We Ensure Transparency and Support Investigator-InitiatedResearch Based on Japan's Clinical Research Act Mitsubishi Tanabe Pharma Corporation (hereaf ter "MTPC"; Head Office:Chuo-ku, Osaka; President & Representative Director: Masayuki Mitsuka)
announced today that MTPC has launched a website as of July 2, 2018,
to publicly call for applicants for Investigator-Initiated Study (IIS) funds.
[Overview of the Open Call]◆Objective :To provide study funds in order to support IIS which use MTPC's pharmaceuticals.
◆Eligible study:
Study using the pharmaceuticals manufactured and marketed by MTPC within therange of approval based on the Pharmaceutical and Medical Device Act◆Eligible Candidates (Applicants) :Principal investigator of the above-mentioned study (medical doctors or dentists
residing in Japan)◆Eligible Fields/Pharmaceuticals/Research Themes:
Study related to the following disease fields, pharmaceuticals, and/or research
themes* (see the next page for details)
Diabetes (Canaglu, Tenelia, Canalia)
Allergic Diseases (Rupafin)◆Application Period:
From Monday, July 2, 2018, to Sunday, March 31, 2019 (for FY 2018)◆How to Apply:
Applications shall be made via the "Open-Call Program for Investigator-InitiatedStudy" on our website.
For details, please check the page for the "Open-Call Program for InvestigatorInitiated Study".
"Open-Call Program for Investigator-Initiated Study"
https://www.mt-pharma.co.jp/shared/show.php?url=../develop/iis/index.html
We will promote appropriate use of our pharmaceuticals by providing support forIIS.

1/2

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media Contacts: TEL: +81 6 6205 5119
Investor Contacts: TEL: +81 6 6205 5110
* Details of the Open Call: Eligible disease fields/pharmaceuticals/research themes
are as follows.
【Diabetes】®

Pharmaceutical Name: Canaglu Tablets 100mg（Generic Name: Canagliflozin)- Study on the efficacy and safety concerning variability of blood glucose levels
in patients with type 2 diabetes mellitus- Study on the mechanism of action of cardioprotection/renoprotection inpatients with type 2 diabetes mellitus- Study on the safety of pathological conditions associated with type 2 diabetes
mellitus- Study on eating habits and exercise therapy in patients with type 2 diabetesmellitus®

Pharmaceutical Name: Tenelia Tablets 20mg （Generic Name: Teneligliptin）- Study on the efficacy and safety concerning variability of blood glucose levels
in elderly patients with type 2 diabetes mellitus- Study on the efficacy and safety of type 2 diabetes mellitus complicated byrenal dysfunction®

Pharmaceutical Name: Canalia Combination Tablets (Generic Name: Teneligliptin /Canagliflozin)- Study on the efficacy and safety concerning variability of blood glucose levels
in patients with type 2 diabetes mellitus- Study on improvement of adherence in patients with type 2 diabetes mellitus【Allergic Diseases】
Pharmaceutical Name: Rupafin®

Tablets 10mg (Generic Name: Rupatadine)- Study on the efficacy and safety concerning allergic rhinitis, urticaria, andskin disease- Study on the efficacy and safety concerning itching sensations due to atopic
dermatitis

2/2